Greenway Earns Two U.S. Patents for Care-Coordination Technology

CARROLLTON, Ga.-- Greenway Medical Technologies, Inc., which delivers innovative information solutions for healthcare providers, has been granted two new U.S. patents related to electronic quality-of-care data liquidity. Both patents cover the receipt and transmission of data from multiple electronic health record (EHR) systems, accessible directly or over the cloud, including data distributed across a vast patient population. Such data liquidity supports improved care coordination, quality, safety and cost-effectiveness.

Patent number 8,428,966 applies to EHR data collected from multiple EHR systems for the purpose of certifications, accreditations and monetary incentives. An enhanced server built on the same architecture as the EHR systems is configured to transmit and receive data in the same format as those systems. The server uses retrieved data to fill in electronic quality-of-care forms, which it transmits to organizations that qualify healthcare providers for certifications, accreditations and monetary incentives.

Patent number 8,438,041 is for similar automation related to tracking clinical events. An enhanced server receives patient data in a common format from multiple EHR systems, tracks it in real time to identify any clinical events, uses the data to fill in electronic clinical event forms and transmits the forms to organizations that keep track of clinical events.

Innovation in Care Coordination

“Tightly orchestrated data flow is central to care coordination, and these inventions provide coordination that goes well beyond what we usually associate with EHRs,” said Johnathan Samples, Greenway® executive vice president of innovation. “By automatically transferring quality-of-care data from multiple systems directly into beneficial communications to key industry organizations, our solutions relieve manual data-processing burdens and help providers stay focused on their core mission of providing the best-possible healthcare experience and outcomes.”

Greenway has two previously issued U.S. patents, for customized templating capabilities and mobile EHR access technology.

As a pioneer in the design and delivery of a fully integrated solution for EHR, practice management and interoperability, Greenway has long maintained a focus on health data liquidity. By working to ensure unimpeded data flow through its own solutions and those of other industry suppliers, Greenway helps healthcare providers stay in front of the changes they face today and those they will face in the future.

About Greenway and PrimeSUITE

Greenway Medical Technologies, Inc. (NYSE: GWAY) delivers smarter solutions for smarter healthcare. PrimeSUITE® — Greenway’s certified and fully integrated electronic health record, practice management and interoperability solution platform — helps improve care coordination, quality and cost-efficiency as part of a smarter, sustainable healthcare system. Thousands of care providers across primary care and more than 30 specialties and sub-specialties use cloud-based, remote-hosted or on-premise Greenway® solutions in healthcare enterprises, physician practices and clinics nationwide. For details, see greenwaymedical.com, Twitter, Facebook or YouTube.

Forward-Looking Statements

In addition to historical information, this press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include both implied and express statements regarding the Company’s financial condition, growth strategy, business development efforts, service offerings, and service delivery models. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from the historical results or from any results expressed or implied by such forward-looking statements. Risks that could affect the Company’s future performance include, but are not limited to, our ability to adapt to evolving technology and industry standards; our ability to implement our growth strategy; our ability to retain management and other qualified personnel; failure to prevent disruptions in service or damage to our third-party providers’ data centers; failure to avoid liability for the use of content we provide; accelerated transition to a subscription pricing model, which would reduce our near-term revenues; regulation of the healthcare information technology industry; our ability to ensure our solutions meet industry and government standards; failure to maintain adequate security measures for our customers’ confidential information and personal identifiable information and their patients’ protected health information; our ability to obtain new provider customers; failure of the HITECH Act and other incentive programs to be fully implemented or funded by the government; our ability to implement our strategic relationships as currently intended; failure to establish, protect or enforce our intellectual property; and restrictions in our credit facility and future indebtedness. Further information concerning these and other factors is included in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012. The Company disclaims any obligation or duty to update or modify these forward-looking statements.

Greenway, the Greenway logo and PrimeSUITE are registered trademarks and the phrase “smarter solutions for smarter healthcare” is a trademark of Greenway Medical Technologies, Inc. Other product or company names are the property of their respective owners.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.